SCHEMBL5129501

SCHEMBL5129501

Cc1cc2c(NCc3ccc(F)cc3)nc(-c3ccncc3)nc2s1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 7/20 0.50
FLT3 P36888 1/20 0.49
PDE5A O76074 5/20 0.49
PTGS2 P35354 2/20 0.49
MEN1 O00255 1/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
KMT2A Q03164 1/20 0.49
PTGS1 P23219 1/20 0.49
TBXAS1 P24557 1/20 0.49
POLB P06746 1/20 0.46
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
USP1 O94782 1/20 0.42
WDR48 Q8TAF3 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5113677 0.90 PDE5A (0.62) PRKCIPDE5APTGS2MEN1LMNA
SCHEMBL5122989 0.87 POLB (0.64) PDE5APTGS2MEN1LMNAMAPT
SCHEMBL5125278 0.87 PRKCI (0.68) PRKCIPDE5APTGS2MEN1LMNA
SCHEMBL5123659 0.86 PDE5A (0.49) PRKCIPDE5APTGS2MEN1LMNA
SCHEMBL5129980 0.86 PRKCI (0.47) PRKCIFLT3PDE5APTGS2PTGS1
SCHEMBL5115713 0.84 PRKCI (0.48) PRKCIPDE5APTGS2MEN1LMNA
SCHEMBL5120390 0.84 MEN1 (0.57) PRKCIPDE5APTGS2MEN1KMT2A
SCHEMBL8182005 0.83 FLT3 (0.49) FLT3PTGS2MEN1LMNAMAPT
SCHEMBL5124775 0.83 KDM4E (0.45) FLT3PDE5AMEN1LMNAMAPT
SCHEMBL5115662 0.82 MAPT (0.53) PRKCIPDE5AMEN1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
US-6432950-B1 ANTICANCER AGENTS; KILLING CANCER CELLS CELL PATHWAYS 2002-08-13 US disclosed
US-6133271-A Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives CELL PATHWAYS, INC. (US) 2000-10-17 US disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 PRKCI 1513/4885FLT3 12/4885PDE5A 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.